Levels offers an AI-powered app that provides personalized metabolic health feedback by integrating continuous glucose monitoring (optional), blood testing, food logging, sleep, and exercise data. The product combines AI food logging, macro tracking, and accountability features such as Habit Loops to help members understand which foods and behaviors work best for their bodies. Levels has amassed more than 700 million glucose data points, hundreds of thousands of food logs, and has helped over 60,000 members. The company is conducting a large IRB-approved research study with global researchers to expand understanding of glucose patterns across diverse populations. To broaden access and scale the product, Levels announced a $10M Series A extension, including a crowdfunding tranche. The company highlights strong community engagement—two crowdfunding rounds, an 18M-view YouTube channel, and 2M+ annual blog visitors—as part of its growth strategy. Founded in 2019 and announced from New York, Levels positions its app as a prevention-first tool to address the metabolic health crisis. Levels offers a mobile application that uses biosensor data (including continuous glucose monitors and Apple Health) to give members real-time feedback on how diet and lifestyle choices impact metabolic health. The company provides a holistic suite of member services: the Levels app, an engaged community, educational materials (podcast and blog), and access to CGMs and on‑demand blood testing to track metabolic markers. Levels says the additional capital will expand access to those services and advance its mission to solve the metabolic health crisis. The company is conducting what it calls the largest-ever study of its kind with researchers worldwide to better understand glucose patterns across diverse populations. Levels’ stated five-year goals include shifting focus from healthcare to prevention, creating transparency in the food industry, and empowering individuals through personal data. Founders include Casey Means, MD; Josh Clemente; Sam Corcos; David Flinner; and Andrew Conner, and the company lists a broad advisory board of clinicians and researchers in metabolic health. Levels develops glucose monitors that integrate with a paired mobile app to help users track glucose. The company had offered services to 25,000 beta testers. It is backed by a16z. In its Series A, Levels raised $38 million at a $300 million valuation. The company plans to expand internationally this year. Levels develops a biowearable metabolic sensor that pairs continuous glucose monitoring (CGM) medical hardware—worn on the arm for two-week periods—with an analytics and coaching software suite to deliver actionable health information. The company positions the product as a behavior-change mechanism to help users close the loop between food, exercise and well-being. Founders Josh Clemente (CEO) and Dr. Casey Means emphasize optimizing metabolic function to improve energy, mood, memory and other outcomes tied to metabolic health. Levels reports a 45,000-person waitlist and says the new funding will let it fulfill all pre-orders and scale to serve millions more. The company will use the capital to grow the team, hit product development milestones, and perform research to identify which mechanisms to prioritize before a full launch. Levels expects customers will be able to purchase the product starting in early 2021.

Total raised

$67M

Funding rounds

4

Latest round

Series A

Latest activity

Aug 2024